Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis

Mehdi Hamadani, Abraham S. Kanate, Alyssa DiGilio, Kwang Woo Ahn, Sonali M. Smith, Jong Wook Lee, Ernesto Ayala, Nelson Chao, Parameswaran Hari, Javier Bolaños-Meade, Ronald Gress, Niels Smedegaard Anderson, Yi Bin Chen, Umar Farooq, Gary Schiller, Jean Yared, Anna Sureda, Timothy S. Fenske, Horatiu Olteanu

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Aggressive NK cell leukemia (ANKL) is an exceedingly rare form of leukemia and carries a poor prognosis, with a median survival of only 2 months. Using the Center for International Blood and Marrow Transplant Research database, we evaluated outcomes of allogeneic hematopoietic cell transplantation (alloHCT) in patients with ANKL. Twenty-one patients with a centrally confirmed diagnosis of ANKL were included. Median patient age was 42 years and 15 patients (71%) were Caucasian. Fourteen patients (67%) were in complete remission (CR) at the time of alloHCT, and 5 patients had active disease. Median follow-up of survivors was 25 months (range, 12 to 116). The 2-year estimates of nonrelapse mortality, relapse/progression, progression-free (PFS), and overall survival (OS) were 21%, 59%, 20%, and 24%, respectively. The 2-year PFS of patients in CR at the time of alloHCT was significantly better than that of patients with active disease at transplantation (30% versus 0%; P = .001). The 2-year OS in similar order was 38% versus 0% (P < .001). In conclusion, this registry analysis that included majority non-Asian patient population shows that alloHCT can provide durable disease control in a subset of ANKL patients. Achieving CR before transplantation appears to be a prerequisite for successful transplantation outcomes.

Original languageEnglish (US)
Pages (from-to)853-856
Number of pages4
JournalBiology of Blood and Marrow Transplantation
Volume23
Issue number5
DOIs
StatePublished - May 1 2017

    Fingerprint

Keywords

  • Aggressive natural killer cell leukemia
  • Allogeneic transplantation
  • Myeloablative
  • Reduced-intensity conditioning

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Hamadani, M., Kanate, A. S., DiGilio, A., Ahn, K. W., Smith, S. M., Lee, J. W., Ayala, E., Chao, N., Hari, P., Bolaños-Meade, J., Gress, R., Smedegaard Anderson, N., Chen, Y. B., Farooq, U., Schiller, G., Yared, J., Sureda, A., Fenske, T. S., & Olteanu, H. (2017). Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation, 23(5), 853-856. https://doi.org/10.1016/j.bbmt.2017.01.082